Selecta Biosciences, Inc.

Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development

14 days ago

• Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report. • Leading companies in hyperuricemia drug development include LG Chem, Shanton Pharma, InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes. • A significant development occurred in December 2024 when Atom Therapeutics partnered with China Medical System Holdings to commercialize lingdolinurad (ABP-671), a novel URAT1 inhibitor for chronic gout and hyperuricemia in China.

Cartesian Therapeutics' Descartes-08 Shows Promise in Myasthenia Gravis Phase 3 Trial

4 months ago

• Cartesian Therapeutics secured FDA agreement for Phase 3 trial of Descartes-08 in myasthenia gravis, potentially leading to BLA submission. • Phase 2b results demonstrated unmatched efficacy and durability with extended dosing intervals and a favorable safety profile. • Descartes-08 offers potential advantages over existing treatments like Vyvgart, providing sustained disease suppression with less frequent dosing. • Analysts maintain a Buy rating for Cartesian Therapeutics, citing the SPA agreement and positive Phase 2b data as confidence boosters.